

Sent via Electronic Delivery to: mabrams@nrxpharma.com; jransom@nrxpharma.com

January 17, 2025

Mr. Michael Abrams
Chief Financial Officer
NRX Pharmaceuticals, Inc.
1201 Orange Street, Suite 600
Wilmington, Delaware 19801

Re: NRX Pharmaceuticals, Inc. (the “Company”)

Dear Mr. Abrams:

On August 6, 2024, Staff notified the Company that it had failed to maintain a minimum market value of listed securities of \$35,000,000 over the previous 30 consecutive business days as required by The Nasdaq Capital Market set forth in Listing Rule 5550(b)(2) (the “Rule”). Since then, Staff has determined that for the last 10 consecutive business days, from January 2 to January 16, 2025, the Company’s market value of listed securities has been \$35,000,000 or greater. Accordingly, the Company has regained compliance with the Rule and this matter is now closed.

If you have any questions, please contact me at + 1 202 748 4488.

Sincerely,



Rachel Scherr
Director
Nasdaq Listing Qualifications